Please assess the completion status of the following clinical trial:

Trial Title: Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients~  * Men and women~ * Ages 18-50 years~ * Patients diagnosed with schizophrenia (SZ), schizoaffective disorder (SZA), or psychotic bipolar disorder (BP).~ * On a stable psychiatric medication regimen for at least a month prior to and during study participation~* Healthy Controls:~  * Men and women~ * Ages 18-50 years~ * Without major psychiatric illness~Exclusion Criteria:~* Patients~  * Any change in psychiatric medications within a month prior to and during study participation~ * Legal or mental incompetency~ * Intellectual disability~ * Substance use disorder (abuse or dependence) with active use within the last 3 months~ * Significant medical or neurological illness~ * Prior neurosurgical procedure~ * History of seizures~ * History of electroconvulsive therapy (ECT) or clinical TMS within the past three months~ * History of participation in a cerebellar TMS study~ * Implanted cardiac pacemakers~ * Patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:~    * Aneurysm clips or coils~   * Carotid or cerebral stents~   * Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt)~   * Magnetically active dental implants~   * Cochlear/otologic implants~   * CSF shunts~   * Ferromagnetic ocular implants~   * Pellets, bullets, fragments less than 30 cm from the coil~   * Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil~ * Pregnant women~* Healthy Controls:~  * History of major psychiatric illness, including psychosis~ * Has a first-degree relative with psychosis~ * Active use of psychotropic medications~ * Legal or mental incompetency~ * Intellectual disability~ * Substance use disorder (abuse or dependence) with active use within the last 3 months~ * Significant medical or neurological illness~ * Prior neurosurgical procedure~ * History of seizures~ * History of ECT treatment or clinical TMS within the past three months~ * History of participation in a cerebellar TMS study~ * Implanted cardiac pacemakers~ * Individuals who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:~    * Aneurysm clips or coils~   * Carotid or cerebral stents~   * Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, transcutaneous electrical nerve stimulation (TENS) unit, or ventriculo-peritoneal shunt)~   * Magnetically active dental implants~   * Cochlear/otologic implants~   * Cerebrospinal fluid (CSF) shunts~   * Ferromagnetic ocular implants~   * Pellets, bullets, fragments less than 30 cm from the coil~   * Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil~ * Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Intermittent TBS (iTBS) (Type: EXPERIMENTAL): Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
- Continuous TBS (cTBS) (Type: ACTIVE_COMPARATOR): Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
- Sham TBS (Type: SHAM_COMPARATOR): Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.

Based on this trial design, predict the completion outcome and termination type (if applicable).